CSL Ltd Annual Report 2020

Product Registrations and Indications 2019/20* Immunology Focus on improved patient convenience, plasma yield improvements, expanded labels, new formulation science, and recombinant technology. Product Type Country/Region HIZENTRA ® Immune Globulin Subcutaneous (Human) 20% Liquid NR Vietnam, Kazakhstan, Russia, Azerbaijan HIZENTRA ® Immune Globulin Subcutaneous (Human) 20% Liquid NI Taiwan, Brazil, Macedonia, Mexico, Ecuador (all CIDP) PRIVIGEN ® Immune Globulin Intravenous (Human) 10% Liquid NR Sri Lanka, Vietnam, Brunei, Paraguay, Nicaragua PRIVIGEN ® Immune Globulin Intravenous (Human) 10% Liquid NI Switzerland (MMN), Japan (PID/SID), Panama (CIPD), Macedonia (MMN), Jordan (CIDP) BERINERT ® , C1-Esterase Inhibitor Intravenous (Human) 2000 IU and 3000 IU NR Switzerland ALBUREX ® 5/20, ALBURX ® 20/25 , Human Albumin, Albuminar 20/5/25, Albuminate 5/20/25 NR France, UK, Malta, Singapore, Indonesia, China, New Zealand, Ecuador Haematology Maximize the value and performance of our existing coagulation therapies and develop newprotein and gene-based therapies. IDELVION ® Coagulation Factor IX (Recombinant) Albumin Fusion Protein NR Singapore, Argentina, South Korea AFSTYLA ® Coagulation Factor VIII (Recombinant) NR Thailand, Singapore, Brazil, Argentina, South Korea, Malaysia BERIATE ® Coagulation Factor VIII (Human) NR Latvia, Estonia, Lithuania, Malta, Vietnam, Singapore, Sri Lanka, Jordan BERIPLEX ® C P/N, Prothrombin Complex (Human) NR NewZealand, Chile, Paraguay CORIFACT ® , FIBROGAMMIN ® , Coagulation Factor XIII Concentrate (Human) NR Iraq HAEMOCOMPLETTAN ® 1g, Fibrinogen Concentrate (Human) NR Singapore Respiratory Develop new treatments for respiratory diseases using our existing plasma derived immunoglobulins and proteins and recombinantmonoclonal antibody technology. ZEMAIRA ® Alpha1 Proteinase Inhibitor (Human) NI Brazil (severe alpha1-antitrypsin deficiency) Influenza Vaccines (Seasonal, Pandemic) Develop products for the prevention of infectious diseases. FLUAD ® QUAD Inactivated Quadrivalent Influenza Vaccine (surface antigen), Adjuvanted NR Australia FLUAD ® QUADRIVALENT (Influenza Vaccine, Adjuvanted) NR US FLUAD ® TETRA (Influenza Vaccine, Adjuvanted) NR Europe FLUCELVAX ® QUAD Influenza Vaccine (surface antigen, inactivated, prepared in cell cultures) NR Canada FLUCELVAX ® QUAD (Influenza Vaccine) NR Taiwan FLUCELVAX ® TETRA (Influenza Vaccine) NR Brazil FLUCELVAX ® TETRA (Influenza Vaccine) NI Brazil (for the prevention of influenza in persons aged two years and older) AFLURIA ® QUAD seasonal egg-based split inactivated quadrivalent influenza vaccine NR South Korea, Argentina AFLURIA ® QUAD seasonal egg-based split inactivated quadrivalent influenza vaccine NI NewZealand (for the prevention of influenza in persons aged three years and over) AFLURIA ® QUAD JUNIOR seasonal egg-based split inactivated quadrivalent influenza vaccine NR NewZealand (for the prevention of influenza in persons aged sixmonths–three years) AFLURIA ® TETRA Inactivated Influenza Vaccine NR Germany, Austria AFLURIA ® seasonal egg-based split trivalent inactivated influenza vaccine PQ WHO FLUAD ® Inactivated Trivalent Influenza Vaccine Adjuvanted NR NewZealand AUDENZ ™ adjuvanted, cell-based pandemic Influenza A (H5N1) vaccine NR US In-LicensedProducts 1,2 CATIONORM ® OTC ophthalmic treatment for dry eyes NR Australia RYALTRIS ® Nasal spray for treatment of symptoms of allergic rhinitis and rhino-conjunctivitis NR Australia * First-time registrations or indications for CSL products in the listed countries/regions over the reporting period. NR=New Registration; NI=New Indication; PQ=Prequalification (via WHO). 1 CATIONORM ® is a registered trademark of Santen SAS. 2 RYALTRIS ® is a registered trademark of Glenmark Specialty SA. CSL Limited Annual Report 2020 29